Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

ClinicalTrials.gov ID: NCT02364999

Public ClinicalTrials.gov record NCT02364999. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.

Study identification

NCT ID
NCT02364999
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
719 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2015
Primary completion
Apr 30, 2017
Completion
Nov 30, 2017
Last update posted
Feb 6, 2019

2015 – 2017

United States locations

U.S. sites
19
U.S. states
8
U.S. cities
15
Facility City State ZIP Site status
Southern Cancer Center, PC Daphne Alabama 36526
Southern Cancer Center, PC Mobile Alabama 36607
Southern Cancer Center, PC Mobile Alabama 36608
Beaver Medical Group, L.P. Highland California 92346
Cancer Center of Central Connecticut New Britain Connecticut 06052
Cancer Center of Central Connecticut Southington Connecticut 06489
Phoebe Putney Memorial Hospital Albany Georgia 31701
Swedish Covenant Hospital Chicago Illinois 60625
Meritus Center for Clinical Research Hagerstown Maryland 21742
Holy Cross Hospital Resource Center Silver Spring Maryland 20902
Maryland Oncology & Hematology, PA Silver Spring Maryland 20904
Holy Cross Hospital, Hospital Pharmacy Silver Spring Maryland 20910
Holy Cross Hospital Silver Spring Maryland 20910
Maryland Oncology & Hematology, PA Wheaton Maryland 20902
St. Joseph's Regional Medical Center Paterson New Jersey 07503
Millennium Oncology Houston Texas 77090
Millennium Oncology Kingwood Texas 77339
Millennium Oncology Shenandoah Texas 77384
Millennium Oncology The Woodlands Texas 77380

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 244 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02364999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 6, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02364999 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →